Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CEPH - CEPHALON -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (25)	12/18/2002 4:58:20 PM
From: Icebrg	Read Replies (2) \| Respond to of 109

>>Dressing things up for a sale?>> No, I don't think so. To re-purchase European marketing rights for their own drugs seems to be a part of their strategy. Earlier during the autumn they "took back" Actiq from Elan. With their relatively strong base in Europe (France) this makes of course a lot of sense. Building up a critical mass of products in Europe should also be helpful if and when they take in new products. Their own pipeline looks IMHO relatively weak. Erik